Efficacy of UFT plus Tamoxifen for Estrogen-Receptor-Positive Breast Cancer and Tamoxif en plus UFT for Estrogen-Receptor-Negative Breast Cancer: Adjuvant Therapy after Administration of Mitomycin

Clinical Drug Investigation

Volumn 23, Issue 11, 2003, Pages 689-699

  Ogita, Masami ^a   Uchino, Junichi ^b   Asaishi, Kazuaki ^c   Kubo, Yoshihiko ^d   Tanabe, Tatsuzo ^e   Hata, Atsunobu ^f   Hirata, Koichi ^g   Mito, Michio ^d  

^a HOKKAIDO CANCER CENTER   (Japan)

^b KUSHIRO ROSAI HOSPITAL   (Japan)

^c Sapporo Kotoni Breast Clinic   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

^e NTT CORPORATION   (Japan)

^f Department of Urology   (Japan)

^g SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; MITOMYCIN C; TAMOXIFEN; TEGAFUR; UFT; URACIL;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; META ANALYSIS; MULTICENTER STUDY; NAUSEA; PIGMENT DISORDER; POSTOPERATIVE CARE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0242509266     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323110-00001     Document Type: Article

References (24)

1. Bianco AR, Placido S, Gallo C, et al. Adjuvant therapy with tamoxifen in operable breast cancer. Lancet 1988; 2: 1095-9
2. Mauriac L, Durand M, Chauvergne J, et al. Adjuvant trial for stage II receptor-positive breast cancer: CMF vs CMF + tamoxifen in a single centre. Breast Cancer Res Treat 1988; 11: 179-86
3. Fisher B, Redmond C, Brown A, et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 1986; 4 (4): 459-71
4. Ingle JN, Everson LK, Wieand HS, et al. Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. J Clin Oncol 1988; 6 (9): 1388-96
5. Enomoto K, Abe O. Postoperative adjuvant chemoendocrine therapy for breast cancer: tegafur vs tegafur + tamoxifen (in Japanese). Jpn J Cancer Clin Suppl 1987; 13: 165-81
6. Tashiro H, Nomura Y, Ohsaki A. A double blind comparative study of tegafur (FT) and UFT (a combination of tegafur and uracil) in advanced breast cancer [in Japanese]. Jpn J Clin Oncol 1994; 24 (4): 212-7
7. Yoshimoto M, Kasumi F, Watanabe S, et al. Ten-year follow-up of mitomycin C single agent adjuvant chemotherapy for breast cancer. In: Taguchi T, Andrysek O, editors. New trends in cancer chemotherapy with mitomycin C. Tokyo: Excerpta Medica, 1987: 58-67
8. Yamase H, Akita S, Takaesu H, et al. Long-term efficacy of mitomycin C as an adjuvant chemotherapy for breast cancer [in Japanese; abstract]. J Jpn Soc Cancer Ther 1982; 17 (8): 2115
9. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of randomised trials. Lancet 1998; 351: 1451-67
10. Japan Mammary Cancer Society. General rule for clinical and pathological record of mammary cancer [in Japanese] 9th ed. Tokyo: Kanahara Shuppan, 1988: 58-67
11. Uchino J, Hata Y, Samejima N, et al. Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Br J Cancer 1994; 69: 767-71
12. Abe O. The role of chemoendocrine agents in postoperative adjuvant therapy for breast cancer: meta-analysis of the first collaborative studies of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETBC). Breast Cancer 1994; 1 (1): 1-9
13. Yoshida M, Abe O, Uchino J, et al. Meta-analysis of the second collaborative study of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) in patients with stage II, estrogen receptor positive breast cancer. Breast Cancer 1997; 4: 93-101
14. Yokoe T. Current diagnosis and treatment of breast cancer [in Japanese]. In: Izuo M, editor. Diagnosis and treatment of breast cancer. Tokyo: Nagai-Syoten, 1990: 185-95
15. Sugimachi K, Maehara Y, Akazawa K, et al. Postoperative chemo-endocrine treatment with mitomycin C, tomoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Breast Cancer Res Treat 1999; 56: 113-24
16. Petru E, Schmahl D. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. Klin Wochenschr 1987; 65: 959-66
17. Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005-18
18. Goldhirsch A, Wood WC, Senn H, et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995; 87: 1441-5
19. Tormey DC, Gray R, Gilchrist K, et al. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. Cancer 1990; 65: 200-6
20. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer; an overview of the randomised trials. Lancet 1998; 351: 1451-67
21. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998; 90: 1601-8
22. Noguchi S, Motomura K, Inaji H, et al. Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer. Cancer 1993; 72: 131-6
23. Butta A, MacLennan K, Flanders KC, et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261-4
24. Brunner N, Yee D, Kern FG, et al. Effect of endocrine therapy on growth of t61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). Eur J Cancer 1993; 29A (4): 562-9